CY1121081T1 - Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων - Google Patents
Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχωνInfo
- Publication number
- CY1121081T1 CY1121081T1 CY181101356T CY181101356T CY1121081T1 CY 1121081 T1 CY1121081 T1 CY 1121081T1 CY 181101356 T CY181101356 T CY 181101356T CY 181101356 T CY181101356 T CY 181101356T CY 1121081 T1 CY1121081 T1 CY 1121081T1
- Authority
- CY
- Cyprus
- Prior art keywords
- samidorphan
- buprenorphin
- alks
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά μια σύνθεση που περιλαμβάνει βουπρενοφρίνη και έναν ανταγωνιστή υποδοχέα οπιούχων μ, όπου η σύνθεση χαρακτηρίζεται από έναν δείκτη δραστηριότητας ανταγωνιστών:αγωνιστών (AAnAI) μεταξύ περίπου 0.7 και περίπου 2.2 όπου = AAnAI/EC50 c max BUP c max ανταγωνιστή / IC 50.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576233P | 2011-12-15 | 2011-12-15 | |
| EP12830900.2A EP2790702B1 (en) | 2011-12-15 | 2012-12-14 | Compositions of buprenorphine and mu-opioid receptor antagonists |
| PCT/IB2012/002900 WO2013088243A1 (en) | 2011-12-15 | 2012-12-14 | Compositions of buprenorphine and mu-opioid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121081T1 true CY1121081T1 (el) | 2019-12-11 |
Family
ID=47757653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101356T CY1121081T1 (el) | 2011-12-15 | 2018-12-18 | Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US8822488B2 (el) |
| EP (3) | EP3415148A1 (el) |
| JP (2) | JP6038170B2 (el) |
| KR (1) | KR101996108B1 (el) |
| CN (2) | CN104159586A (el) |
| AU (1) | AU2012351806C1 (el) |
| BR (1) | BR112014012409B8 (el) |
| CA (1) | CA2858812C (el) |
| CY (1) | CY1121081T1 (el) |
| DK (1) | DK3153171T3 (el) |
| EA (1) | EA030609B8 (el) |
| ES (2) | ES2692771T3 (el) |
| HR (1) | HRP20181950T1 (el) |
| HU (1) | HUE041883T2 (el) |
| IL (1) | IL232785B (el) |
| LT (1) | LT3153171T (el) |
| MX (1) | MX375348B (el) |
| PL (1) | PL3153171T3 (el) |
| PT (1) | PT3153171T (el) |
| RS (1) | RS58322B1 (el) |
| SI (1) | SI3153171T1 (el) |
| SM (1) | SMT201800664T1 (el) |
| TR (1) | TR201815154T4 (el) |
| WO (1) | WO2013088243A1 (el) |
| ZA (1) | ZA201405029B (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE043963T2 (hu) | 2009-12-04 | 2019-09-30 | Alkermes Pharma Ireland Ltd | Morfinán származékok gyógyszer-túladagolás kezelésére |
| PT3446565T (pt) | 2010-08-23 | 2024-01-29 | Alkermes Pharma Ireland Ltd | Métodos para tratar o aumento de peso induzido por antipsicóticos |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| CA2858812C (en) | 2011-12-15 | 2019-02-26 | Alkermes Pharma Ireland Limited | Compositions of buprenorphine and mu-opioid receptor antagonists |
| US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| WO2014190270A1 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| TWI768557B (zh) | 2015-02-02 | 2022-06-21 | 美商佛瑪治療公司 | 作為ｈｄａｃ抑制劑之3-烷基-4-醯胺基-雙環[4,5,0]羥肟酸 |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH581624A5 (el) | 1970-08-14 | 1976-11-15 | Sumitomo Chemical Co | |
| US3856795A (en) | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
| US4032529A (en) | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| US3957793A (en) | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4127577A (en) | 1975-11-24 | 1978-11-28 | Sterling Drug Inc. | Aminomethanobenzazocine process |
| US4205171A (en) | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4649200A (en) | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| US4939264A (en) | 1986-07-14 | 1990-07-03 | Abbott Laboratories | Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies |
| US5258386A (en) | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
| US5607941A (en) | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
| SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
| EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
| ATE229958T1 (de) | 1996-01-10 | 2003-01-15 | Glaxosmithkline Spa | Heterocyclische kondensierte morphin-derivate |
| GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| AU2002227135B2 (en) | 2000-10-31 | 2008-01-03 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| WO2003079945A1 (en) * | 2002-03-20 | 2003-10-02 | Euro-Celtique S.A. | Method of administering buprenorphine to treat depression |
| AU2003239389A1 (en) | 2002-05-30 | 2003-12-19 | Eli Lilly And Company | Opioid receptor antagonists |
| AU2005245403B2 (en) | 2004-05-14 | 2012-04-19 | Janssen Pharmaceutica N.V. | Carboxamido opioid compounds |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| WO2006052710A1 (en) | 2004-11-05 | 2006-05-18 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
| ES2440590T3 (es) | 2005-03-02 | 2014-01-29 | Takeda Gmbh | Nuevas sales de derivados de hexahidrofenantridina 6-heterociclil-sustituidos |
| EP2134330B1 (en) | 2007-03-19 | 2013-05-08 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| ES2586245T3 (es) | 2007-08-09 | 2016-10-13 | Rensselaer Polytechnic Institute | Carboxamidas cuaternarias opioides |
| WO2009103004A1 (en) * | 2008-02-14 | 2009-08-20 | Alkermes, Inc. | Selective opioid compounds |
| WO2009126931A2 (en) * | 2008-04-11 | 2009-10-15 | Xvasive, Inc. | Combination therapy for bipolar disorder |
| EP2408303A4 (en) * | 2009-03-19 | 2012-07-25 | Alkermes Inc | MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY |
| US20120149724A1 (en) | 2009-06-04 | 2012-06-14 | The General Hospital Corporation | Modulating endogenous beta-endorphin levels |
| US8530479B2 (en) * | 2009-08-10 | 2013-09-10 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides |
| HUE043963T2 (hu) * | 2009-12-04 | 2019-09-30 | Alkermes Pharma Ireland Ltd | Morfinán származékok gyógyszer-túladagolás kezelésére |
| US9211293B2 (en) * | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| CA2858812C (en) | 2011-12-15 | 2019-02-26 | Alkermes Pharma Ireland Limited | Compositions of buprenorphine and mu-opioid receptor antagonists |
| US9656961B2 (en) * | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
-
2012
- 2012-12-14 CA CA2858812A patent/CA2858812C/en active Active
- 2012-12-14 SM SM20180664T patent/SMT201800664T1/it unknown
- 2012-12-14 WO PCT/IB2012/002900 patent/WO2013088243A1/en active Application Filing
- 2012-12-14 EP EP18187096.5A patent/EP3415148A1/en not_active Withdrawn
- 2012-12-14 HU HUE16201359A patent/HUE041883T2/hu unknown
- 2012-12-14 ES ES16201359.3T patent/ES2692771T3/es active Active
- 2012-12-14 AU AU2012351806A patent/AU2012351806C1/en not_active Ceased
- 2012-12-14 DK DK16201359.3T patent/DK3153171T3/en active
- 2012-12-14 EA EA201491153A patent/EA030609B8/ru unknown
- 2012-12-14 EP EP12830900.2A patent/EP2790702B1/en active Active
- 2012-12-14 PT PT16201359T patent/PT3153171T/pt unknown
- 2012-12-14 MX MX2014007042A patent/MX375348B/es active IP Right Grant
- 2012-12-14 KR KR1020147016224A patent/KR101996108B1/ko not_active Expired - Fee Related
- 2012-12-14 PL PL16201359T patent/PL3153171T3/pl unknown
- 2012-12-14 EP EP16201359.3A patent/EP3153171B1/en active Active
- 2012-12-14 JP JP2014546667A patent/JP6038170B2/ja not_active Expired - Fee Related
- 2012-12-14 US US13/715,198 patent/US8822488B2/en active Active
- 2012-12-14 ES ES12830900T patent/ES2791764T3/es active Active
- 2012-12-14 CN CN201280062291.6A patent/CN104159586A/zh active Pending
- 2012-12-14 RS RS20181543A patent/RS58322B1/sr unknown
- 2012-12-14 BR BR112014012409A patent/BR112014012409B8/pt not_active IP Right Cessation
- 2012-12-14 SI SI201231474T patent/SI3153171T1/sl unknown
- 2012-12-14 CN CN201611052441.1A patent/CN106727562B/zh not_active Expired - Fee Related
- 2012-12-14 LT LTEP16201359.3T patent/LT3153171T/lt unknown
- 2012-12-14 TR TR2018/15154T patent/TR201815154T4/tr unknown
-
2014
- 2014-05-25 IL IL232785A patent/IL232785B/en active IP Right Grant
- 2014-07-10 ZA ZA2014/05029A patent/ZA201405029B/en unknown
- 2014-07-29 US US14/445,407 patent/US9498474B2/en active Active
-
2016
- 2016-03-10 US US15/066,567 patent/US9918978B2/en active Active
- 2016-07-29 JP JP2016150353A patent/JP6403726B2/ja not_active Expired - Fee Related
- 2016-09-12 US US15/262,628 patent/US9913837B2/en active Active
-
2017
- 2017-09-28 US US15/718,139 patent/US10314838B2/en active Active
- 2017-10-02 US US15/722,408 patent/US10188643B2/en active Active
-
2018
- 2018-11-22 HR HRP20181950TT patent/HRP20181950T1/hr unknown
- 2018-12-18 CY CY181101356T patent/CY1121081T1/el unknown
-
2019
- 2019-04-25 US US16/394,524 patent/US10806731B2/en active Active
-
2020
- 2020-10-06 US US17/063,892 patent/US20210196703A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121081T1 (el) | Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων | |
| CY1123365T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| EA201300869A1 (ru) | Морфинановые соединения | |
| CY1123590T1 (el) | Θεραπειες που βασιζονται σε προσδετη χημειοαισθητηριου υποδοχεα | |
| CY1117696T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ | |
| MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| CY1118352T1 (el) | Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη | |
| DK2522667T3 (da) | Morphinanforbindelser | |
| ECSP14003642A (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| ME01532B (me) | Jedinjenja | |
| CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
| JO3346B1 (ar) | مواد مضادة C5aR | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
| JO3131B1 (ar) | مركبات كيميائية | |
| PH12012501783A1 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| CY1120661T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 σεροτονινης για χρηση στη θεραπεια των αλλοιωτικων αιθουσαιων διαταραχων | |
| MX2013005246A (es) | Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano. | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| EA201301114A1 (ru) | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент | |
| MA32945B1 (fr) | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique | |
| CY1120920T1 (el) | Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο |